
var savedState = '{"tables":{"joined":{"name":"joined","data":[{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_CA1_AT8","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":10,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":26296.4,"Region volume estimation":9.46209,"CERAD Scale":"C","No of cells/volume (mm3)":2779.13230586,"Total markers counted":189,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":0.000018135963,"CE Gundersen":0.08,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_CA1_BetaA","% Occupied by plaques":2.07408968246,"Region":"CA1","Disease progression":10,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":178,"Total population estimated":4892.03,"Region volume estimation":4.27762,"CERAD Scale":"C","No of cells/volume (mm3)":1143.63360934,"Total markers counted":178,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_CA1_NISSL","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":10,"Labeling":"NISSL","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":37592.59,"Region volume estimation":4.4191,"CERAD Scale":"C","No of cells/volume (mm3)":8506.84302233,"Total markers counted":140,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_CA1_NeuN","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":10,"Labeling":"NeuN","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":97515.26,"Region volume estimation":8.3626,"CERAD Scale":"C","No of cells/volume (mm3)":11660.878195799998,"Total markers counted":616,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.06,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_CA1_PHF1","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":10,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":28116.74,"Region volume estimation":7.92214,"CERAD Scale":"C","No of cells/volume (mm3)":3549.13445104,"Total markers counted":291,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.13,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_CA3_AT8","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":10,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":7635.69,"Region volume estimation":12.9471,"CERAD Scale":"C","No of cells/volume (mm3)":589.760641379,"Total markers counted":63,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":0.000032493275,"CE Gundersen":0.12,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_CA3_BetaA","% Occupied by plaques":0.63786762193,"Region":"CA3","Disease progression":10,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":70,"Total population estimated":1923.83,"Region volume estimation":9.80008,"CERAD Scale":"C","No of cells/volume (mm3)":196.30758116299998,"Total markers counted":70,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_CA3_NISSL","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":10,"Labeling":"NISSL","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":43231.48,"Region volume estimation":3.70157,"CERAD Scale":"C","No of cells/volume (mm3)":11679.228003299999,"Total markers counted":161,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.03,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_CA3_NeuN","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":10,"Labeling":"NeuN","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":51092.61,"Region volume estimation":4.30513,"CERAD Scale":"C","No of cells/volume (mm3)":11867.843712,"Total markers counted":1291,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.13,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_CA3_PHF1","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":10,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":6183.75,"Region volume estimation":8.70846,"CERAD Scale":"C","No of cells/volume (mm3)":710.085365266,"Total markers counted":64,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_DG_AT8","% Occupied by plaques":"NaN","Region":"DG","Disease progression":10,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":12504.92,"Region volume estimation":14.3734,"CERAD Scale":"C","No of cells/volume (mm3)":870.0043135239999,"Total markers counted":455,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":0.000053683460999999995,"CE Gundersen":0.11,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_DG_BetaA","% Occupied by plaques":1.28443780136,"Region":"DG","Disease progression":10,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":79,"Total population estimated":3126.5,"Region volume estimation":13.0673,"CERAD Scale":"C","No of cells/volume (mm3)":239.261362332,"Total markers counted":79,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.15,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_DG_PHF1","% Occupied by plaques":"NaN","Region":"DG","Disease progression":10,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":1209.27,"Region volume estimation":7.7157,"CERAD Scale":"C","No of cells/volume (mm3)":156.728488666,"Total markers counted":44,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_SUB_AT8","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":10,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":4947,"Region volume estimation":11.7524,"CERAD Scale":"C","No of cells/volume (mm3)":420.935298322,"Total markers counted":125,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":0.000041636898,"CE Gundersen":0.1,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_SUB_BetaA","% Occupied by plaques":3.88301439458,"Region":"SUB","Disease progression":10,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":108,"Total population estimated":2968.2,"Region volume estimation":3.18275,"CERAD Scale":"C","No of cells/volume (mm3)":932.589741576,"Total markers counted":108,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":90,"Plaque AVG volume":"NaN","CE Gundersen":0.1,"MMSE (1)":14,"Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":80,"Patient":"Az01","Post-mortem delay (hours)":4.5,"Gender":"H","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az01_SUB_PHF1","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":10,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":4274.21,"Region volume estimation":5.9261800000000004,"CERAD Scale":"C","No of cells/volume (mm3)":721.2420142489999,"Total markers counted":108,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":"NaN"},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_CA1_AT8","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":12,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":32762.28,"Region volume estimation":13.3045,"CERAD Scale":"C","No of cells/volume (mm3)":2462.49614792,"Total markers counted":173,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":0.000018622039,"CE Gundersen":0.07,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_CA1_BetaA","% Occupied by plaques":1.3083523078100001,"Region":"CA1","Disease progression":12,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":198,"Total population estimated":5441.7,"Region volume estimation":7.74528,"CERAD Scale":"C","No of cells/volume (mm3)":702.582734259,"Total markers counted":198,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_CA1_NISSL","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":12,"Labeling":"NISSL","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":91654.32,"Region volume estimation":9.07284,"CERAD Scale":"C","No of cells/volume (mm3)":10102.0540426,"Total markers counted":256,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_CA1_NeuN","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":12,"Labeling":"NeuN","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":77094.05,"Region volume estimation":4.94815,"CERAD Scale":"C","No of cells/volume (mm3)":15580.378525299999,"Total markers counted":487,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_CA1_PHF1","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":12,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":35556.56,"Region volume estimation":7.26285,"CERAD Scale":"C","No of cells/volume (mm3)":4895.67593989,"Total markers counted":368,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.15,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_CA3_AT8","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":12,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":6678.45,"Region volume estimation":6.381069999999999,"CERAD Scale":"C","No of cells/volume (mm3)":1046.60346932,"Total markers counted":48,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":0.000051865031,"CE Gundersen":0.13,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_CA3_BetaA","% Occupied by plaques":1.17291067184,"Region":"CA3","Disease progression":12,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":57,"Total population estimated":1566.55,"Region volume estimation":6.92714,"CERAD Scale":"C","No of cells/volume (mm3)":226.146721446,"Total markers counted":57,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_CA3_NISSL","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":12,"Labeling":"NISSL","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":51555.55,"Region volume estimation":6.4403,"CERAD Scale":"C","No of cells/volume (mm3)":8005.14727575,"Total markers counted":144,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_CA3_NeuN","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":12,"Labeling":"NeuN","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":57780.96,"Region volume estimation":5.829219999999999,"CERAD Scale":"C","No of cells/volume (mm3)":9912.29701401,"Total markers counted":365,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.13,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_CA3_PHF1","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":12,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":2453.71,"Region volume estimation":6.81802,"CERAD Scale":"C","No of cells/volume (mm3)":359.88600796099996,"Total markers counted":62,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_DG_AT8","% Occupied by plaques":"NaN","Region":"DG","Disease progression":12,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":11350.62,"Region volume estimation":14.8856,"CERAD Scale":"C","No of cells/volume (mm3)":762.523512657,"Total markers counted":413,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":0.000054899359000000006,"CE Gundersen":0.15,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_DG_BetaA","% Occupied by plaques":0.9947377211740001,"Region":"DG","Disease progression":12,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":46,"Total population estimated":1820.5,"Region volume estimation":10.0473,"CERAD Scale":"C","No of cells/volume (mm3)":181.192957312,"Total markers counted":46,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.11,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_DG_PHF1","% Occupied by plaques":"NaN","Region":"DG","Disease progression":12,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":3403.54,"Region volume estimation":7.3106800000000005,"CERAD Scale":"C","No of cells/volume (mm3)":465.557239545,"Total markers counted":86,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.11,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_SUB_AT8","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":12,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":3047.35,"Region volume estimation":6.1429800000000006,"CERAD Scale":"C","No of cells/volume (mm3)":496.070311152,"Total markers counted":77,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":0.000082100313,"CE Gundersen":0.09,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_SUB_BetaA","% Occupied by plaques":6.85397092602,"Region":"SUB","Disease progression":12,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":137,"Total population estimated":3765.22,"Region volume estimation":4.51017,"CERAD Scale":"C","No of cells/volume (mm3)":834.8288423719999,"Total markers counted":137,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":82,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":15,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":70,"Patient":"Az02","Post-mortem delay (hours)":2,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az02_SUB_PHF1","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":12,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":15459.36,"Region volume estimation":4.95938,"CERAD Scale":"C","No of cells/volume (mm3)":3117.19610113,"Total markers counted":160,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":0},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_CA1_AT8","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":2,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":26134.07,"Region volume estimation":8.52308,"CERAD Scale":"C","No of cells/volume (mm3)":3066.27064395,"Total markers counted":207,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":0.000030922564,"CE Gundersen":0.05,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_CA1_BetaA","% Occupied by plaques":2.56144161368,"Region":"CA1","Disease progression":2,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":358,"Total population estimated":9839.03,"Region volume estimation":11.878,"CERAD Scale":"C","No of cells/volume (mm3)":828.3406297360001,"Total markers counted":358,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.06,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_CA1_NISSL","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":2,"Labeling":"NISSL","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":110271.6,"Region volume estimation":10.4941,"CERAD Scale":"C","No of cells/volume (mm3)":10507.9616165,"Total markers counted":308,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_CA1_NeuN","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":2,"Labeling":"NeuN","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":119994.43,"Region volume estimation":7.71276,"CERAD Scale":"C","No of cells/volume (mm3)":15557.9105275,"Total markers counted":758,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_CA1_PHF1","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":2,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":54687.54,"Region volume estimation":8.638689999999999,"CERAD Scale":"C","No of cells/volume (mm3)":6330.53622714,"Total markers counted":566,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.13,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_CA3_AT8","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":2,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":7575.09,"Region volume estimation":6.2477,"CERAD Scale":"C","No of cells/volume (mm3)":1212.4605855,"Total markers counted":60,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":0.000042548652000000003,"CE Gundersen":0.1,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_CA3_BetaA","% Occupied by plaques":1.04479056577,"Region":"CA3","Disease progression":2,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":95,"Total population estimated":3759.72,"Region volume estimation":15.3113,"CERAD Scale":"C","No of cells/volume (mm3)":245.551977951,"Total markers counted":95,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_CA3_NISSL","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":2,"Labeling":"NISSL","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":73037.03,"Region volume estimation":8.19585,"CERAD Scale":"C","No of cells/volume (mm3)":8911.46494872,"Total markers counted":204,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_CA3_NeuN","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":2,"Labeling":"NeuN","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":112395.84,"Region volume estimation":8.9396,"CERAD Scale":"C","No of cells/volume (mm3)":12572.8041523,"Total markers counted":710,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.14,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_CA3_PHF1","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":2,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":2137.1,"Region volume estimation":9.685989999999999,"CERAD Scale":"C","No of cells/volume (mm3)":220.638262067,"Total markers counted":54,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_DG_AT8","% Occupied by plaques":"NaN","Region":"DG","Disease progression":2,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":9735.7,"Region volume estimation":8.31664,"CERAD Scale":"C","No of cells/volume (mm3)":1170.62900402,"Total markers counted":369,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":0.00004215698,"CE Gundersen":0.1,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_DG_BetaA","% Occupied by plaques":0.9628069376189999,"Region":"DG","Disease progression":2,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":109,"Total population estimated":4313.78,"Region volume estimation":18.8881,"CERAD Scale":"C","No of cells/volume (mm3)":228.386126715,"Total markers counted":109,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_DG_PHF1","% Occupied by plaques":"NaN","Region":"DG","Disease progression":2,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":6541.03,"Region volume estimation":8.653089999999999,"CERAD Scale":"C","No of cells/volume (mm3)":755.9184060260001,"Total markers counted":238,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_SUB_AT8","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":2,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":9146.8,"Region volume estimation":6.10824,"CERAD Scale":"C","No of cells/volume (mm3)":1497.45262138,"Total markers counted":142,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":0.000058789438,"CE Gundersen":0.08,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_SUB_BetaA","% Occupied by plaques":5.13923604446,"Region":"SUB","Disease progression":2,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":163,"Total population estimated":4479.78,"Region volume estimation":5.124569999999999,"CERAD Scale":"C","No of cells/volume (mm3)":874.176760196,"Total markers counted":163,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":81,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":79,"Patient":"Az03","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"SI","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az03_SUB_PHF1","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":2,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":14493.16,"Region volume estimation":5.70656,"CERAD Scale":"C","No of cells/volume (mm3)":2539.73672405,"Total markers counted":150,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.1,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_CA1_AT8","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":9,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":19505.87,"Region volume estimation":8.12645,"CERAD Scale":"B","No of cells/volume (mm3)":2400.29410136,"Total markers counted":103,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":0.00001993507,"CE Gundersen":0.08,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_CA1_BetaA","% Occupied by plaques":4.781589102130001,"Region":"CA1","Disease progression":9,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":174,"Total population estimated":4782.1,"Region volume estimation":1.9937200000000002,"CERAD Scale":"B","No of cells/volume (mm3)":2398.58154605,"Total markers counted":174,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.11,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_CA1_NISSL","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":9,"Labeling":"NISSL","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":11692.8,"Region volume estimation":4.68107,"CERAD Scale":"B","No of cells/volume (mm3)":2497.89043958,"Total markers counted":84,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_CA1_NeuN","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":9,"Labeling":"NeuN","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":17888.35,"Region volume estimation":5.58985,"CERAD Scale":"B","No of cells/volume (mm3)":3200.14848341,"Total markers counted":113,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_CA1_PHF1","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":9,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":80871.85,"Region volume estimation":6.31642,"CERAD Scale":"B","No of cells/volume (mm3)":12803.4313741,"Total markers counted":837,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.14,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_CA3_AT8","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":9,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":9468.87,"Region volume estimation":17.5884,"CERAD Scale":"B","No of cells/volume (mm3)":538.358804667,"Total markers counted":50,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":0.000050355328,"CE Gundersen":0.09,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_CA3_BetaA","% Occupied by plaques":2.95204230352,"Region":"CA3","Disease progression":9,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":127,"Total population estimated":3517.87,"Region volume estimation":6.00071,"CERAD Scale":"B","No of cells/volume (mm3)":586.242294662,"Total markers counted":127,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_CA3_NISSL","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":9,"Labeling":"NISSL","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":45111.11,"Region volume estimation":7.1310199999999995,"CERAD Scale":"B","No of cells/volume (mm3)":6326.03891168,"Total markers counted":168,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_CA3_NeuN","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":9,"Labeling":"NeuN","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":23195.93,"Region volume estimation":11.8524,"CERAD Scale":"B","No of cells/volume (mm3)":1957.06607944,"Total markers counted":844,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":1,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_CA3_PHF1","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":9,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":40001.13,"Region volume estimation":10.9232,"CERAD Scale":"B","No of cells/volume (mm3)":3662.03401933,"Total markers counted":414,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_DG_AT8","% Occupied by plaques":"NaN","Region":"DG","Disease progression":9,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":30552.67,"Region volume estimation":13.6157,"CERAD Scale":"B","No of cells/volume (mm3)":2243.9294344,"Total markers counted":772,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":0.000055294555,"CE Gundersen":0.07,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_DG_BetaA","% Occupied by plaques":2.98967585414,"Region":"DG","Disease progression":9,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":250,"Total population estimated":9893.99,"Region volume estimation":18.2991,"CERAD Scale":"B","No of cells/volume (mm3)":540.681782164,"Total markers counted":250,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_DG_PHF1","% Occupied by plaques":"NaN","Region":"DG","Disease progression":9,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":6173.86,"Region volume estimation":13.7594,"CERAD Scale":"B","No of cells/volume (mm3)":448.70125150800004,"Total markers counted":156,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.12,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_SUB_AT8","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":9,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":2928.62,"Region volume estimation":5.69193,"CERAD Scale":"B","No of cells/volume (mm3)":514.52143649,"Total markers counted":74,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":0.000030196979,"CE Gundersen":0.07,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_SUB_BetaA","% Occupied by plaques":13.2137133424,"Region":"SUB","Disease progression":9,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":243,"Total population estimated":6678.45,"Region volume estimation":1.52621,"CERAD Scale":"B","No of cells/volume (mm3)":4375.83949784,"Total markers counted":243,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":87,"Plaque AVG volume":"NaN","CE Gundersen":0.1,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":78,"Patient":"Az04","Post-mortem delay (hours)":5.5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"IV","Diabetes":"NaN","measure_id":"Az04_SUB_PHF1","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":9,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":10241.84,"Region volume estimation":4.439030000000001,"CERAD Scale":"B","No of cells/volume (mm3)":2307.22477658,"Total markers counted":106,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.06,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_CA1_AT8","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":14,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":47533.71,"Region volume estimation":15.3683,"CERAD Scale":"C","No of cells/volume (mm3)":3092.97124601,"Total markers counted":251,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":0.000047241613,"CE Gundersen":0.08,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_CA1_BetaA","% Occupied by plaques":1.78120859238,"Region":"CA1","Disease progression":14,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":172,"Total population estimated":4727.13,"Region volume estimation":12.5374,"CERAD Scale":"C","No of cells/volume (mm3)":377.04228947,"Total markers counted":172,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_CA1_NISSL","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":14,"Labeling":"NISSL","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":123787.03,"Region volume estimation":8.07739,"CERAD Scale":"C","No of cells/volume (mm3)":15325.1272998,"Total markers counted":461,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_CA1_NeuN","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":14,"Labeling":"NeuN","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":221378.23,"Region volume estimation":12.3703,"CERAD Scale":"C","No of cells/volume (mm3)":17895.9467434,"Total markers counted":895,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.06,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_CA1_PHF1","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":14,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":23672.17,"Region volume estimation":6.57228,"CERAD Scale":"C","No of cells/volume (mm3)":3601.82006853,"Total markers counted":245,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.16,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_CA3_AT8","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":14,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":5147.97,"Region volume estimation":12.5821,"CERAD Scale":"C","No of cells/volume (mm3)":409.150300824,"Total markers counted":37,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":0.000032414722999999996,"CE Gundersen":0.13,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_CA3_BetaA","% Occupied by plaques":0.593067870729,"Region":"CA3","Disease progression":14,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":62,"Total population estimated":1703.97,"Region volume estimation":9.31322,"CERAD Scale":"C","No of cells/volume (mm3)":182.96249847,"Total markers counted":62,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_CA3_NISSL","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":14,"Labeling":"NISSL","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":46453.7,"Region volume estimation":5.51832,"CERAD Scale":"C","No of cells/volume (mm3)":8418.08738892,"Total markers counted":173,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_CA3_NeuN","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":14,"Labeling":"NeuN","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":67120.89,"Region volume estimation":7.47588,"CERAD Scale":"C","No of cells/volume (mm3)":8978.32629737,"Total markers counted":424,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.18,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_CA3_PHF1","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":14,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":1266.43,"Region volume estimation":11.3104,"CERAD Scale":"C","No of cells/volume (mm3)":111.970398925,"Total markers counted":32,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.13,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_DG_AT8","% Occupied by plaques":"NaN","Region":"DG","Disease progression":14,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":1703.97,"Region volume estimation":18.227999999999998,"CERAD Scale":"C","No of cells/volume (mm3)":93.4809084924,"Total markers counted":62,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":0.000025255949,"CE Gundersen":0.09,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_DG_BetaA","% Occupied by plaques":0.518945659758,"Region":"DG","Disease progression":14,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":119,"Total population estimated":4709.54,"Region volume estimation":22.9203,"CERAD Scale":"C","No of cells/volume (mm3)":205.474622933,"Total markers counted":119,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.11,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_DG_PHF1","% Occupied by plaques":"NaN","Region":"DG","Disease progression":14,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":2308.6,"Region volume estimation":17.0739,"CERAD Scale":"C","No of cells/volume (mm3)":135.212224506,"Total markers counted":84,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.1,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_SUB_AT8","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":14,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":10048.59,"Region volume estimation":11.7207,"CERAD Scale":"C","No of cells/volume (mm3)":857.33701912,"Total markers counted":104,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":0.000031923748,"CE Gundersen":0.09,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_SUB_BetaA","% Occupied by plaques":1.53896938717,"Region":"SUB","Disease progression":14,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":135,"Total population estimated":3710.25,"Region volume estimation":7.696389999999999,"CERAD Scale":"C","No of cells/volume (mm3)":482.076661916,"Total markers counted":135,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":83,"Plaque AVG volume":"NaN","CE Gundersen":0.1,"MMSE (1)":23,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az05","Post-mortem delay (hours)":4,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V/VI","Diabetes":"NaN","measure_id":"Az05_SUB_PHF1","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":14,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":7407.62,"Region volume estimation":8.40342,"CERAD Scale":"C","No of cells/volume (mm3)":881.500627126,"Total markers counted":92,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"Cardiopatía isquémica","Details of the cerebral atrophy":"Fronto-temporal","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_CA1_AT8","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":7,"Labeling":"AT8","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":24050.92,"Region volume estimation":9.68187,"CERAD Scale":"C","No of cells/volume (mm3)":2484.11928687,"Total markers counted":127,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":0.000021105465,"CE Gundersen":0.09,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_CA1_BetaA","% Occupied by plaques":1.1394717377399999,"Region":"CA1","Disease progression":7,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":129,"Total population estimated":3545.35,"Region volume estimation":6.56675,"CERAD Scale":"C","No of cells/volume (mm3)":539.89416378,"Total markers counted":129,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_CA1_NISSL","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":7,"Labeling":"NISSL","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":48601.85,"Region volume estimation":6.785939999999999,"CERAD Scale":"C","No of cells/volume (mm3)":7162.13965935,"Total markers counted":181,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_CA1_NeuN","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":7,"Labeling":"NeuN","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":48727.95,"Region volume estimation":6.9503699999999995,"CERAD Scale":"C","No of cells/volume (mm3)":7010.84258824,"Total markers counted":197,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_CA1_PHF1","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":7,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":65315.86,"Region volume estimation":5.76224,"CERAD Scale":"C","No of cells/volume (mm3)":11335.1509135,"Total markers counted":676,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.12,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_CA3_AT8","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":7,"Labeling":"AT8","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":6500.36,"Region volume estimation":11.897,"CERAD Scale":"C","No of cells/volume (mm3)":546.386483988,"Total markers counted":73,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":0.000046726668,"CE Gundersen":0.24,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_CA3_BetaA","% Occupied by plaques":0.189115078897,"Region":"CA3","Disease progression":7,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":17,"Total population estimated":467.22,"Region volume estimation":11.5441,"CERAD Scale":"C","No of cells/volume (mm3)":40.4726223785,"Total markers counted":17,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_CA3_NISSL","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":7,"Labeling":"NISSL","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":58537.04,"Region volume estimation":5.94644,"CERAD Scale":"C","No of cells/volume (mm3)":9844.0478673,"Total markers counted":218,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_CA3_NeuN","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":7,"Labeling":"NeuN","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":29761.15,"Region volume estimation":8.56751,"CERAD Scale":"C","No of cells/volume (mm3)":3473.72223668,"Total markers counted":188,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_CA3_PHF1","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":7,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":11691.15,"Region volume estimation":9.6292,"CERAD Scale":"C","No of cells/volume (mm3)":1214.13513064,"Total markers counted":121,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_DG_AT8","% Occupied by plaques":"NaN","Region":"DG","Disease progression":7,"Labeling":"AT8","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":5540.64,"Region volume estimation":16.2104,"CERAD Scale":"C","No of cells/volume (mm3)":341.795390613,"Total markers counted":140,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":0.000040393805,"CE Gundersen":0.09,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_DG_BetaA","% Occupied by plaques":0.933270969781,"Region":"DG","Disease progression":7,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":125,"Total population estimated":4986.58,"Region volume estimation":21.5829,"CERAD Scale":"C","No of cells/volume (mm3)":231.04309430200001,"Total markers counted":125,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_DG_PHF1","% Occupied by plaques":"NaN","Region":"DG","Disease progression":7,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":4177.46,"Region volume estimation":12.593,"CERAD Scale":"C","No of cells/volume (mm3)":331.72873818799997,"Total markers counted":152,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.1,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_SUB_AT8","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":7,"Labeling":"AT8","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":10435.08,"Region volume estimation":9.18112,"CERAD Scale":"C","No of cells/volume (mm3)":1136.5802865,"Total markers counted":108,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":0.000065622273,"CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_SUB_BetaA","% Occupied by plaques":3.9822426320499997,"Region":"SUB","Disease progression":7,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":149,"Total population estimated":4095.02,"Region volume estimation":6.748069999999999,"CERAD Scale":"C","No of cells/volume (mm3)":606.843141817,"Total markers counted":149,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":76,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":69,"Patient":"Az06","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"V","Diabetes":"SI","measure_id":"Az06_SUB_PHF1","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":7,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NO","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":14654.15,"Region volume estimation":5.6744699999999995,"CERAD Scale":"C","No of cells/volume (mm3)":2582.47025713,"Total markers counted":182,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Demencia","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Global","MMSE (2)":4},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_CA1_AT8","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":0,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":17391.79,"Region volume estimation":7.412210000000001,"CERAD Scale":"C","No of cells/volume (mm3)":2346.37038076,"Total markers counted":125,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":0.000014434571000000001,"CE Gundersen":0.09,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_CA1_BetaA","% Occupied by plaques":1.06582539404,"Region":"CA1","Disease progression":0,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":129,"Total population estimated":3545.35,"Region volume estimation":4.8015,"CERAD Scale":"C","No of cells/volume (mm3)":738.3838383839999,"Total markers counted":129,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_CA1_NISSL","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":0,"Labeling":"NISSL","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":21436.8,"Region volume estimation":2.51173,"CERAD Scale":"C","No of cells/volume (mm3)":8534.67530348,"Total markers counted":154,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.06,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_CA1_NeuN","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":0,"Labeling":"NeuN","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":42900.38,"Region volume estimation":4.78742,"CERAD Scale":"C","No of cells/volume (mm3)":8961.06462353,"Total markers counted":271,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.06,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_CA1_PHF1","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":0,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":24155.26,"Region volume estimation":3.05764,"CERAD Scale":"C","No of cells/volume (mm3)":7899.96860324,"Total markers counted":250,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.18,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_CA3_AT8","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":0,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":6060.07,"Region volume estimation":12.0887,"CERAD Scale":"C","No of cells/volume (mm3)":501.30038796599996,"Total markers counted":32,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":0.000037035758,"CE Gundersen":0.12,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_CA3_BetaA","% Occupied by plaques":0.9805885920190001,"Region":"CA3","Disease progression":0,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":73,"Total population estimated":2006.28,"Region volume estimation":7.5775,"CERAD Scale":"C","No of cells/volume (mm3)":264.768063345,"Total markers counted":73,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_CA3_NISSL","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":0,"Labeling":"NISSL","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":57194.44,"Region volume estimation":5.247330000000001,"CERAD Scale":"C","No of cells/volume (mm3)":10899.722334999999,"Total markers counted":213,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_CA3_NeuN","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":0,"Labeling":"NeuN","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":92766.14,"Region volume estimation":7.91534,"CERAD Scale":"C","No of cells/volume (mm3)":11719.792201,"Total markers counted":586,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.14,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_CA3_PHF1","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":0,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":6817.58,"Region volume estimation":11.4758,"CERAD Scale":"C","No of cells/volume (mm3)":594.083201171,"Total markers counted":49,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.06,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_DG_AT8","% Occupied by plaques":"NaN","Region":"DG","Disease progression":0,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":14445.24,"Region volume estimation":13.6638,"CERAD Scale":"C","No of cells/volume (mm3)":1057.19053265,"Total markers counted":365,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":0.000052100832,"CE Gundersen":0.16,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_DG_BetaA","% Occupied by plaques":0.46128877838699994,"Region":"DG","Disease progression":0,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":39,"Total population estimated":1543.46,"Region volume estimation":17.4328,"CERAD Scale":"C","No of cells/volume (mm3)":88.5376990501,"Total markers counted":39,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_DG_PHF1","% Occupied by plaques":"NaN","Region":"DG","Disease progression":0,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":6760.9,"Region volume estimation":13.8943,"CERAD Scale":"C","No of cells/volume (mm3)":486.59522250099997,"Total markers counted":246,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_SUB_AT8","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":0,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":3655.28,"Region volume estimation":2.3311900000000003,"CERAD Scale":"C","No of cells/volume (mm3)":1567.98888122,"Total markers counted":133,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":0.000031864168,"CE Gundersen":0.18,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_SUB_BetaA","% Occupied by plaques":1.0359359477299999,"Region":"SUB","Disease progression":0,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":31,"Total population estimated":851.98,"Region volume estimation":2.62059,"CERAD Scale":"C","No of cells/volume (mm3)":325.109994314,"Total markers counted":31,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":89,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":"NaN","Depression/Anxiety/Mood disorders":"NaN","Age at diagnosis":89,"Patient":"Az07","Post-mortem delay (hours)":4.25,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az07_SUB_PHF1","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":0,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"NaN","Total nucleators counted":"NaN","Total population estimated":5659.37,"Region volume estimation":1.38496,"CERAD Scale":"C","No of cells/volume (mm3)":4086.30574168,"Total markers counted":143,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"NaN","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"NaN","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_CA1_AT8","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":8,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":24528.87,"Region volume estimation":6.23688,"CERAD Scale":"C","No of cells/volume (mm3)":3932.87509139,"Total markers counted":238,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":0.000039817637,"CE Gundersen":0.08,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_CA1_BetaA","% Occupied by plaques":3.2096625519099997,"Region":"CA1","Disease progression":8,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":163,"Total population estimated":7466.31,"Region volume estimation":9.262369999999999,"CERAD Scale":"C","No of cells/volume (mm3)":806.09066578,"Total markers counted":163,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_CA1_NISSL","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":8,"Labeling":"NISSL","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":26314.81,"Region volume estimation":3.36301,"CERAD Scale":"C","No of cells/volume (mm3)":7824.77899263,"Total markers counted":147,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.06,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_CA1_NeuN","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":8,"Labeling":"NeuN","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":61219.12,"Region volume estimation":8.12397,"CERAD Scale":"C","No of cells/volume (mm3)":7535.61620735,"Total markers counted":297,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_CA1_PHF1","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":8,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":37843.26,"Region volume estimation":3.9307800000000004,"CERAD Scale":"C","No of cells/volume (mm3)":9627.41745913,"Total markers counted":470,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.12,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_CA3_AT8","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":8,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":16000.45,"Region volume estimation":12.5582,"CERAD Scale":"C","No of cells/volume (mm3)":1274.10377283,"Total markers counted":69,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":0.00008559827300000001,"CE Gundersen":0.21,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_CA3_BetaA","% Occupied by plaques":1.05726103336,"Region":"CA3","Disease progression":8,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":23,"Total population estimated":1053.53,"Region volume estimation":8.52962,"CERAD Scale":"C","No of cells/volume (mm3)":123.51429489200001,"Total markers counted":23,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.06,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_CA3_NISSL","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":8,"Labeling":"NISSL","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":60864.2,"Region volume estimation":5.222090000000001,"CERAD Scale":"C","No of cells/volume (mm3)":11655.1419068,"Total markers counted":340,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.04,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_CA3_NeuN","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":8,"Labeling":"NeuN","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":112263.91,"Region volume estimation":9.009889999999999,"CERAD Scale":"C","No of cells/volume (mm3)":12460.075539200001,"Total markers counted":851,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_CA3_PHF1","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":8,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":16908.69,"Region volume estimation":9.80591,"CERAD Scale":"C","No of cells/volume (mm3)":1724.33665004,"Total markers counted":210,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_DG_AT8","% Occupied by plaques":"NaN","Region":"DG","Disease progression":8,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":23679.64,"Region volume estimation":25.9818,"CERAD Scale":"C","No of cells/volume (mm3)":911.3933599669999,"Total markers counted":359,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":0.000064788391,"CE Gundersen":0.14,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_DG_BetaA","% Occupied by plaques":1.16924751548,"Region":"DG","Disease progression":8,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":52,"Total population estimated":3429.92,"Region volume estimation":19.0053,"CERAD Scale":"C","No of cells/volume (mm3)":180.47176314,"Total markers counted":52,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_DG_PHF1","% Occupied by plaques":"NaN","Region":"DG","Disease progression":8,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":3206.39,"Region volume estimation":10.6147,"CERAD Scale":"C","No of cells/volume (mm3)":302.070713256,"Total markers counted":140,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.15,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_SUB_AT8","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":8,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":3100.12,"Region volume estimation":4.35228,"CERAD Scale":"C","No of cells/volume (mm3)":712.297922009,"Total markers counted":47,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":0.000050304152,"CE Gundersen":0.09,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_SUB_BetaA","% Occupied by plaques":4.86896474581,"Region":"SUB","Disease progression":8,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":124,"Total population estimated":5679.89,"Region volume estimation":5.8682300000000005,"CERAD Scale":"C","No of cells/volume (mm3)":967.905143459,"Total markers counted":124,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":85,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":7,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":77,"Patient":"Az08","Post-mortem delay (hours)":5.75,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"SI","measure_id":"Az08_SUB_PHF1","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":8,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":10225.73,"Region volume estimation":4.82299,"CERAD Scale":"C","No of cells/volume (mm3)":2120.20551567,"Total markers counted":127,"Hypercholesterolemia":"SI","Visuospatial agnosia":"NaN","Details on family history of dementia":"NaN","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical / Cerebelosa","MMSE (2)":"NaN"},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.11,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_CA1_AT8","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":8,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":7301.77,"Region volume estimation":6.76807,"CERAD Scale":"C","No of cells/volume (mm3)":1078.85556739,"Total markers counted":82,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":0.000019727927999999998,"CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_CA1_BetaA","% Occupied by plaques":2.46529301058,"Region":"CA1","Disease progression":8,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":160,"Total population estimated":4397.33,"Region volume estimation":3.5188599999999997,"CERAD Scale":"C","No of cells/volume (mm3)":1249.64619223,"Total markers counted":160,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.13,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_CA1_NISSL","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":8,"Labeling":"NISSL","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":15777.47,"Region volume estimation":3.07417,"CERAD Scale":"C","No of cells/volume (mm3)":5132.26984845,"Total markers counted":62,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.11,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_CA1_NeuN","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":8,"Labeling":"NeuN","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":13139.23,"Region volume estimation":3.60391,"CERAD Scale":"C","No of cells/volume (mm3)":3645.82633862,"Total markers counted":83,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_CA1_PHF1","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":8,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":45025.43,"Region volume estimation":3.0726299999999998,"CERAD Scale":"C","No of cells/volume (mm3)":14653.710339399999,"Total markers counted":466,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.12,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_CA3_AT8","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":8,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":10017.68,"Region volume estimation":9.151019999999999,"CERAD Scale":"C","No of cells/volume (mm3)":1094.70638246,"Total markers counted":72,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":0.000047851004000000004,"CE Gundersen":0.13,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_CA3_BetaA","% Occupied by plaques":0.9119434168889999,"Region":"CA3","Disease progression":8,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":67,"Total population estimated":1841.38,"Region volume estimation":9.66199,"CERAD Scale":"C","No of cells/volume (mm3)":190.57978739400002,"Total markers counted":67,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_CA3_NISSL","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":8,"Labeling":"NISSL","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":35712.96,"Region volume estimation":3.84956,"CERAD Scale":"C","No of cells/volume (mm3)":9277.15375264,"Total markers counted":133,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_CA3_NeuN","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":8,"Labeling":"NeuN","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":25803.55,"Region volume estimation":6.8960300000000005,"CERAD Scale":"C","No of cells/volume (mm3)":3741.797817,"Total markers counted":163,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_CA3_PHF1","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":8,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":19034.36,"Region volume estimation":8.45172,"CERAD Scale":"C","No of cells/volume (mm3)":2252.12856081,"Total markers counted":197,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_DG_AT8","% Occupied by plaques":"NaN","Region":"DG","Disease progression":8,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":9339.94,"Region volume estimation":13.5683,"CERAD Scale":"C","No of cells/volume (mm3)":688.364791462,"Total markers counted":236,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":0.000055345797,"CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_DG_BetaA","% Occupied by plaques":2.66488735562,"Region":"DG","Disease progression":8,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":169,"Total population estimated":6688.34,"Region volume estimation":13.8907,"CERAD Scale":"C","No of cells/volume (mm3)":481.497692701,"Total markers counted":169,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_DG_PHF1","% Occupied by plaques":"NaN","Region":"DG","Disease progression":8,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":4040.05,"Region volume estimation":7.38662,"CERAD Scale":"C","No of cells/volume (mm3)":546.941632303,"Total markers counted":147,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.11,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_SUB_AT8","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":8,"Labeling":"AT8","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":3363.96,"Region volume estimation":4.41378,"CERAD Scale":"C","No of cells/volume (mm3)":762.1494501310001,"Total markers counted":85,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":0.000026736404,"CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_SUB_BetaA","% Occupied by plaques":2.44133821093,"Region":"SUB","Disease progression":8,"Labeling":"BetaA","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":144,"Total population estimated":3957.6,"Region volume estimation":4.33418,"CERAD Scale":"C","No of cells/volume (mm3)":913.1138992839999,"Total markers counted":144,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":84,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":18,"Depression/Anxiety/Mood disorders":"NO","Age at diagnosis":76,"Patient":"Az09","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NO","Braak Scale":"VI","Diabetes":"NaN","measure_id":"Az09_SUB_PHF1","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":8,"Labeling":"PHF1","Apraxia / Instrumental impairment":"SI","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":6846.65,"Region volume estimation":3.14414,"CERAD Scale":"C","No of cells/volume (mm3)":2177.59069253,"Total markers counted":173,"Hypercholesterolemia":"SI","Visuospatial agnosia":"SI","Details on family history of dementia":"Alzheimer","Details of cardiovascular diseases":"Hipertensión arterial","Details of the cerebral atrophy":"Cortico-subcortical","MMSE (2)":8},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.09,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_CA1_AT8","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":9,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":19896.21,"Region volume estimation":5.936719999999999,"CERAD Scale":"C","No of cells/volume (mm3)":3351.3808971999997,"Total markers counted":143,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":0.000035062645,"CE Gundersen":0.07,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_CA1_BetaA","% Occupied by plaques":14.5282341106,"Region":"CA1","Disease progression":9,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":241,"Total population estimated":6623.48,"Region volume estimation":1.5985200000000002,"CERAD Scale":"C","No of cells/volume (mm3)":4143.50774466,"Total markers counted":241,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_CA1_NISSL","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":9,"Labeling":"NISSL","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":45111.11,"Region volume estimation":3.58575,"CERAD Scale":"C","No of cells/volume (mm3)":12580.662344,"Total markers counted":168,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.06,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_CA1_NeuN","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":9,"Labeling":"NeuN","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":67526.55,"Region volume estimation":3.99635,"CERAD Scale":"C","No of cells/volume (mm3)":16897.056063699998,"Total markers counted":273,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_CA1_PHF1","% Occupied by plaques":"NaN","Region":"CA1","Disease progression":9,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":36909.26,"Region volume estimation":4.35273,"CERAD Scale":"C","No of cells/volume (mm3)":8479.56569785,"Total markers counted":382,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.13,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_CA3_AT8","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":9,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":10983.89,"Region volume estimation":14.5269,"CERAD Scale":"C","No of cells/volume (mm3)":756.106946424,"Total markers counted":58,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":0.000101973969,"CE Gundersen":0.09,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_CA3_BetaA","% Occupied by plaques":5.7658866412,"Region":"CA3","Disease progression":9,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":137,"Total population estimated":3765.22,"Region volume estimation":6.65907,"CERAD Scale":"C","No of cells/volume (mm3)":565.427304413,"Total markers counted":137,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_CA3_NISSL","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":9,"Labeling":"NISSL","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":50212.96,"Region volume estimation":6.887989999999999,"CERAD Scale":"C","No of cells/volume (mm3)":7289.92928271,"Total markers counted":187,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_CA3_NeuN","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":9,"Labeling":"NeuN","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":67754.11,"Region volume estimation":8.13743,"CERAD Scale":"C","No of cells/volume (mm3)":8326.22953439,"Total markers counted":428,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_CA3_PHF1","% Occupied by plaques":"NaN","Region":"CA3","Disease progression":9,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":16812.07,"Region volume estimation":14.4454,"CERAD Scale":"C","No of cells/volume (mm3)":1163.83554626,"Total markers counted":174,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.05,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_DG_AT8","% Occupied by plaques":"NaN","Region":"DG","Disease progression":9,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":16344.89,"Region volume estimation":12.4119,"CERAD Scale":"C","No of cells/volume (mm3)":1316.8725175000002,"Total markers counted":413,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":0.000064859621,"CE Gundersen":0.07,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_DG_BetaA","% Occupied by plaques":3.4291607272699998,"Region":"DG","Disease progression":9,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":216,"Total population estimated":8548.42,"Region volume estimation":16.1686,"CERAD Scale":"C","No of cells/volume (mm3)":528.705020843,"Total markers counted":216,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.07,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_DG_PHF1","% Occupied by plaques":"NaN","Region":"DG","Disease progression":9,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":6266.2,"Region volume estimation":16.8293,"CERAD Scale":"C","No of cells/volume (mm3)":372.33871878199994,"Total markers counted":228,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.2,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_SUB_AT8","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":9,"Labeling":"AT8","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":1028.98,"Region volume estimation":1.3166,"CERAD Scale":"C","No of cells/volume (mm3)":781.543369285,"Total markers counted":26,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":0.000055788676,"CE Gundersen":0.08,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_SUB_BetaA","% Occupied by plaques":10.182133951299999,"Region":"SUB","Disease progression":9,"Labeling":"BetaA","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":172,"Total population estimated":4727.13,"Region volume estimation":2.59003,"CERAD Scale":"C","No of cells/volume (mm3)":1825.1255777,"Total markers counted":172,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21},{"Decease age":80,"Plaque AVG volume":"NaN","CE Gundersen":0.08,"MMSE (1)":27,"Depression/Anxiety/Mood disorders":"SI","Age at diagnosis":71,"Patient":"Az10","Post-mortem delay (hours)":5,"Gender":"M","Initial behavior alteration":"NaN","Braak Scale":"V","Diabetes":"NaN","measure_id":"Az10_SUB_PHF1","% Occupied by plaques":"NaN","Region":"SUB","Disease progression":9,"Labeling":"PHF1","Apraxia / Instrumental impairment":"NaN","Language impairment":"SI","Total nucleators counted":"NaN","Total population estimated":17101.93,"Region volume estimation":3.9407400000000004,"CERAD Scale":"C","No of cells/volume (mm3)":4339.77628567,"Total markers counted":177,"Hypercholesterolemia":"NaN","Visuospatial agnosia":"SI","Details on family history of dementia":"DCL","Details of cardiovascular diseases":"NaN","Details of the cerebral atrophy":"Ganglios Basales","MMSE (2)":21}],"schema":{"dataset_type":"TABLE","index":"measure_id","attributes":{"measure_id":{"attribute_type":"CATEGORICAL","spatial":false,"key":true,"shape":[],"continuous":false,"name":"measure_id"},"Patient":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Patient"},"Labeling":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Labeling"},"Region":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Region"},"Region volume estimation":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":true,"name":"Region volume estimation"},"No of cells/volume (mm3)":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":true,"name":"No of cells/volume (mm3)"},"Total markers counted":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Total markers counted"},"Total population estimated":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":true,"name":"Total population estimated"},"Plaque AVG volume":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Plaque AVG volume"},"% Occupied by plaques":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":false,"name":"% Occupied by plaques"},"Total nucleators counted":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Total nucleators counted"},"CE Gundersen":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":true,"name":"CE Gundersen"},"Gender":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Gender"},"Decease age":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Decease age"},"Age at diagnosis":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Age at diagnosis"},"Disease progression":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Disease progression"},"Post-mortem delay (hours)":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":true,"name":"Post-mortem delay (hours)"},"Braak Scale":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Braak Scale"},"CERAD Scale":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"CERAD Scale"},"MMSE (1)":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":false,"name":"MMSE (1)"},"MMSE (2)":{"attribute_type":"QUANTITATIVE","spatial":false,"key":false,"shape":[],"continuous":false,"name":"MMSE (2)"},"Initial behavior alteration":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Initial behavior alteration"},"Depression/Anxiety/Mood disorders":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Depression/Anxiety/Mood disorders"},"Apraxia / Instrumental impairment":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Apraxia / Instrumental impairment"},"Language impairment":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Language impairment"},"Visuospatial agnosia":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Visuospatial agnosia"},"Diabetes":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Diabetes"},"Hypercholesterolemia":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Hypercholesterolemia"},"Details of cardiovascular diseases":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Details of cardiovascular diseases"},"Details of the cerebral atrophy":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Details of the cerebral atrophy"},"Details on family history of dementia":{"attribute_type":"CATEGORICAL","spatial":false,"key":false,"shape":[],"continuous":false,"name":"Details on family history of dementia"}},"quantitative_attrs":["% Occupied by plaques","Age at diagnosis","CE Gundersen","Decease age","Disease progression","MMSE (1)","MMSE (2)","No of cells/volume (mm3)","Plaque AVG volume","Post-mortem delay (hours)","Region volume estimation","Total markers counted","Total nucleators counted","Total population estimated"]},"selection":"joined_dselect"}},"conditions":{},"layout":[{"x":0,"y":0,"w":12,"h":11,"i":"c0","handle":".card-anchor"}],"cards":{"c0":{"kind":"pcp","title":"joined","config":{"table":"joined","columns":[{"name":"Total population estimated","included":true},{"name":"% Occupied by plaques","included":true},{"name":"No of cells/volume (mm3)","included":true},{"name":"Total markers counted","included":true},{"name":"CE Gundersen","included":true},{"name":"Gender","included":true},{"name":"Decease age","included":true}]},"key":"c0"}}}';

module.exports = savedState;
